Observations in the diseased cohort and in matched controls from the non-diseased cohort are used to determine excess costs and QoL changes attributable to CAP.Based on an estimated @,@ CAPiTA participants being hospitalized with CAP and an assumed CHO-CAP participation rate of @ % of all CAPiTA participants ( @,@ ) , @ CAP episodes are expected among CHO-CAP participants ( the `` diseased '' cohort ) .